# Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

> **NCT07561892** · PHASE4 · RECRUITING · sponsor: **Fujian Medical University Union Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Newly Diagnosed
- Chemotherapy Effect

## Interventions

- **DRUG:** daunomycin/Idarubicin+ Silybinin
- **DRUG:** daunomycin/Idarubicin

## Key facts

- **NCT ID:** NCT07561892
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07561892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07561892, "Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07561892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*